Contineum Therapeutics (CTNM) Current Leases (2023 - 2026)

Contineum Therapeutics' Current Leases history runs 4 years deep, the most recent figure standing at $2.4 million for Q2 2026.

• In Q2 2026, Current Leases rose 63.23% year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $2.4 million (up 63.23% YoY), while the FY2025 annual figure was $2.3 million, up 61.23% from the prior year.
• Current Leases for Q2 2026 stood at $2.4 million, up from $2.3 million in the prior quarter.
• The five-year high for Current Leases was $2.4 million in Q2 2026, with the low at $464000.0 in Q4 2023.
• The 4-year median for Current Leases is $1.5 million (2025), against an average of $1.4 million.
• The sharpest annual moves came in 2024 and 2026: Current Leases surged 212.93% in 2024, then surged 58.28% in 2026.
• Contineum Therapeutics' Current Leases stood at $464000.0 in 2023, then soared by 212.93% to $1.5 million in 2024, then surged by 61.23% to $2.3 million in 2025, then climbed by 2.22% to $2.4 million in 2026.
• Business Quant data shows CTNM's Current Leases at $2.4 million in Q2 2026, $2.3 million in Q1 2026, and $2.3 million in Q4 2025.